June 22, 2018
Santhera’s Raxone Early Acces to Medicines Scheme renewed in UK
Santhera Pharmaceuticals’s Raxone has been renewed in UK, as the nation’s Medicines and Healthcare products Regulatory Agency (MHRA) has renewed…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Raxone
June 13, 2018
Santhera Pharmaceuticals submits NDA in South Korea for Raxone for the treatment of LHON
Santhera Pharmaceuticals said on Tuesday that the Korean Ministry of Food and Drug Safety (MFDS) has accepted its new drug…
March 5, 2018
Santhera’s study shows safety profile of idebenone at higher dose than now approved for Raxone in Leber’s hereditary optic neuropathy
An investigator-initiated trial at the National Institutes of Health (NIH) in an exploratory Phase I/II clinical trial in primary progressive…
January 29, 2018
Santhera reports net revenues 21% up in 2017 from its lead product Raxone, amid negative opinion by CHMP for it in DMD
Santhera Pharmaceuticals has reported an increase of 21% year-on-year in net revenues to CHF 22.9 million (2016: CHF 19.0 million)…
January 26, 2018
EMA confirms negative stand for Santhera’s Raxone extension application in Duchene
Santhera Pharmaceuticals will still remain without extension application for Raxone in Duchenne muscular dystrophy (DMD) in Europe, as expected. The…
August 31, 2017
Santhera cleared for visual impairment treatment Raxone in Israel
Santhera Pharmaceuticals has been cleared in Israel for Raxone (idebenone) for visual impairment in adolescents and older, with Leber’s hereditary optic neuropathy (LHON).